Key result
Intravenous nicotine clears ~23% slower in elderly versus younger adults without clinical significance.
Why the study?
Does age affect the pharmacokinetics and pharmacodynamics of nicotine in healthy subjects?
Population
40 healthy subjects, comprising 20 elderly subjects (age 65-76 years) and 20 adult subjects (age 22-43 years)
Comparison
Intravenous infusion of 0.028 mg/kg of nicotine… vs Healthy adult subjects receiving the same…
Design
Cohort
Authors
Loading...
May support standard nicotine dosing in healthy elderly; leaves open confirmation in comorbid or polypharmacy populations.
Does age affect the pharmacokinetics and pharmacodynamics of nicotine in healthy subjects?
Although statistically significant differences in nicotine disposition exist between elderly and younger adults, they do not appear clinically important, supporting the use of standard nicotine replacement strategies in older populations.
Lars Molander (2001) studied Healthy (n=40). Nicotine vs. Younger adults was evaluated on Nicotine pharmacokinetics (total clearance, nonrenal clearance, renal clearance, volume of distribution). Intravenous nicotine in healthy elderly subjects significantly decreased total clearance (-23%) and renal clearance (-49%) compared with younger adults, though not to a clinically important extent.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: